Dihydroquercetin
description1
description2
Basic information
Product Name: Dihydroquercetin
IUPAC Name: (2R,3R)-2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydrochromen-4-one
CAS No.: 480-18-2
Molecular Formula: C₁₅H₁₂O₇
Physicochemical Properties:
Parameter |
Value/Description |
Appearance |
White or off white powder |
Melting Point |
240–242°C (decomposition) |
Solubility |
0.5 mg/mL in water; soluble in ethanol/acetone |
logP |
1.8 (amphiphilic) |
pKa |
7.2 (7-OH), 9.5 (4'-OH) |
Stability |
Light-sensitive; stable at pH 5–7 |
Quality Standard: CP2020,JP,Customer Made
Specification
Test Items |
Standard |
Dihydroquercetin (CAS: 480-18-2) |
98% by HPLC |
Loss on drying |
≤5.0% |
Total ash |
≤5.0% |
Structural Stability
Multi-Target Action
High Safety
1. Molecular Target Network
2. Pharmacokinetics
Absorption
15% oral bioavailability (enhanced by gut microbiota metabolism).
Distribution
High in liver/kidneys; low BBB penetration (<1%).
Metabolism
Hepatic UGT1A1-mediated glucuronidation.
Excretion
Primarily biliary (75% clearance in 48h).
Clinical Applications
Indications & Protocols
Condition |
Regimen |
Evidence |
Non-Alcoholic Fatty Liver |
100 mg tid ×12 weeks |
↓25% liver fat* |
Atherosclerosis |
50 mg bid ×6 months |
↓0.1 mm carotid IMT |
Diabetic Complications |
150 mg/day (Phase II) |
↓30% microalbuminuria |
*Randomized controlled trial (n=200)
Special Populations
Hepatic Impairment: Reduce dose 30% (Child-Pugh B).
Pregnancy: No teratogenicity in animals (limited human data).
Dosage and Administration
Formulations
Tablets: 50 mg/tablet (β-cyclodextrin inclusion complex).
Injection: 10 mg/mL (dilute in glucose).
Nutraceuticals: 95% purity capsules.
Dosing Guidelines
Use |
Dose |
Duration |
Antioxidant |
50–100 mg/day |
Long-term |
Metabolic Syndrome |
100–300 mg/day |
3–6 months |
Acute Liver Injury |
200 mg IV qd |
7–14 days |
Safety Evaluation
Adverse Reactions
System |
Incidence |
Manifestations |
Gastrointestinal |
5% |
Mild diarrhea |
Hypersensitivity |
0.3% |
Rash |
Hepatic |
<1% |
Reversible ALT↑ |
Contraindications & Interactions
Absolute CI:
Flavonoid allergy.
Severe hypotension (SBP <90 mmHg).
Cautions:CYP3A4 substrates (e.g., statins): Risk of metabolic inhibition.
Research Progress Green max
Novel Formulations
Nanostructured Lipid Carriers: ↑Oral bioavailability to 35%.
Transdermal Microemulsions: ↑8× skin permeability.
New Indications
Alzheimer’s Disease: Reduces Aβ plaques (↓40% in animal models).
COVID-19: Inhibits 3CL protease (IC₅₀=22 μM).
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.